[1] ShidaD,HamaguchiT,OchiaiH. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer:Using a propensity score analysis[J]. Ann Surg Oncol, 2016, 23(11):1-7. [2] Winner M, Mooney SJ, Hershman DL, et al. Incidence and pre-dictors of bowel obstruction in elderly patients with stage Ⅳ colon cancer:a population-based cohort study[J]. JAMA Surg,2013,148(8):715-722. [3] Ishihara S,NishikawaT,TanakaT,et al. Benefit of primary tumor resection in stage Ⅳ colorectal cancer with unresectable metastasis:a multicenter retrospective study using a propensity score analysis[J]. Int J Colorectal Dis, 2015, 30(6):807-812. [4] Kim MJ, Lee HS, Kim JH, et al. Different metastatic pattern according to the KRAS mutational status and site-specificdiscordance of KRAS status in patients with colorectal cancer[J]. BMC Cancer, 2012, 12:347. [5] Kim YW, Kim IY. The role of surgery for asymptomatic primarytumors in unresectable stage Ⅳ colorectal cancer[J]. Ann Coloproctol,2013,29(2):44-54. [6] Yang TX, Billah B, Morris DL, et al. Primary colorectal cancer palliative resection:early results after laparoscopic colectomy and open system review and meta-analysis[J]. Colorectal Dis, 2013, 15(8):407-419. [7] TurnerN,TranB,TranPV,et al. Primary tumor resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival[J].Clin Colorectal Cancer, 2015, 10(3):185-191. [8] Ikoma N, Rodriguez-Bigas MA. Managing the primary tumor with unresectable synchronous colorectal metastases[J].Curr Colorectal Cancer Rep, 2016, 12(3):170-179. [9] Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage Ⅳ colorectal cancer receiving combination chemotherapy without surgery as initial treatment[J]. J Clin Oncol,2009,27(20):3379-3384. [10] Ahmed S, Shahid RK, Leis A, et al. Should noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis[J]. Curr Oncol,2013,20(5):e420-e441. [11] Hu J,Yan WY,Xie L,et al. Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer[J]. Medicine(Baltimore), 2016, 95(50):e5649. [12] Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage Ⅱ and Ⅲ resected colon cancer:results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial[J]. J Clin Oncol, 2010, 28(3):466-474. [13] Verhoef C, de Wilt JH, Burger JW, et al. Surgery of the primaryin stage Ⅳ colorectal cancer with unresectable metastases[J]. Eur J Cancer,2011,47(Suppl 3):S61-S66. [14] Evans MD, Escofet X, Karandikar SS, et al. In colorectal cancer management of patients with resection and non surgical strategy results in the late[J]. World J Surg Oncol, 2009, 7(1):28. [15] 苏燕燕,杨羽中,董兵,等.右半结肠癌小淋巴结的检出及对病理分期的影响[J].解放军医学杂志,2016,41(10):879-890. [16] Modest DP, Stintzing S, Laubender RP, et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status[J]. Anticancer Drugs, 2011, 22(9):913-918. [17] Gonzalez-Aguilera JJ, Oliart S, Azcoita MM, et al. Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer[J]. Am J Clin Oncol, 2004, 27(1):39-45. [18] Krzysztof R, Bogdan Z,Wojciech JO,et al. Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy-and radiotherapy-treated colorectal adenocarcinoma patients[J]. Mol Diagn Ther,2014,18(5):559-566. [19] Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype[J]. Ann Oncol, 2002, 13(9):1438-1446. [20] Zhang J, Zheng J, Yang YH, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3 mutations in Chinese colorectal cancer patients:analysis of 1110 cases[J]. Sci Rep, 2015, 5:18678. |